Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 17/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.48 |
| ▸ | PDE4A | P27815 | 5/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15745980 | 0.80 | BRAF (0.47) | BRAFMAPK3MAPK1PDE10APDE4B | |
| SCHEMBL3272752 | 0.75 | MAPK14 (0.43) | BRAFMAPK1RPS6KA3 | |
| SCHEMBL21051439 | 0.75 | NPC1 (0.42) | RPS6KA3 | |
| SCHEMBL8119242 | 0.73 | PRMT5 (0.48) | BRAFMAPK3MAPK1PDE10APDE4B | |
| SCHEMBL10508644 | 0.72 | HIF1A (0.53) | MAPK1PDE10APDE4BPDE4APDE3B | |
| SCHEMBL1758462 | 0.72 | SMN1; SMN2 (0.39) | PDE10ARPS6KA3PDE4BPDE4APDE3B | |
| SCHEMBL5449991 | 0.72 | KDR (0.52) | BRAFMAPK3MAPK1PDE10APDE4B | |
| SCHEMBL4137079 | 0.72 | BRAF (0.42) | BRAFMAPK3MAPK1PDE10APDE4B | |
| SCHEMBL21051395 | 0.71 | ESR1 (0.40) | MAPK1 | |
| SCHEMBL1960709 | 0.71 | MAPT (0.65) | RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117751107-A | Organic pyridine-pyrazole compounds and uses thereof | 博善人工智能剑桥有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023007184-A1 | ORGANIC PYRIDINE-PYRAZOLE COMPOUNDS AND THEIR USES | Benevolentai Cambridge Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
| EP-1979343-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | Pfizer Products Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007077490-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PDE12, PDE10A, PDE7A | BRAF 1849/4885MAPK3 1396/4885MAPK1 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.